VEXRX | WAMVX | VEXRX / WAMVX | |
Total Expense Ratio | N/A | N/A | - |
Annual Report Gross Expense Ratio | N/A | N/A | - |
Fund Existence | 23 years | 22 years | - |
Gain YTD | 5.035 | 2.632 | 191% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 50000 | 2000 | 2,500% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 22.1B | 356M | 6,208% |
Annual Yield % from dividends | 0.58 | 0.00 | - |
Returns for 1 year | 10.04 | 30.00 | 33% |
Returns for 3 years | 8.11 | 15.95 | 51% |
Returns for 5 years | 14.59 | 28.06 | 52% |
Returns for 10 years | 32.27 | 58.05 | 56% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
HCAYX | 57.14 | 0.26 | +0.46% |
Hartford Capital Appreciation Y | |||
NEQCX | 12.15 | 0.02 | +0.16% |
Neuberger Berman U.S. Equity Impact C | |||
MGINX | 10.27 | N/A | N/A |
DWS Global Macro Inst | |||
MCSSX | 39.46 | -0.08 | -0.20% |
NYLI WMC Enduring Capital Investor Class | |||
FBTTX | 24.11 | -0.13 | -0.54% |
Fidelity Advisor Biotechnology M |